



**FIG. 1**

Reduction in HSV1 infectivity after treatment with various concentrations of apoE derived peptides




**FIG. 2**

**Reduction in HSV2 infectivity after treatment with various concentrations of apoE derived peptides**




**FIG. 3**

Reduction in HIV infectivity after treatment with various concentrations of apoE derived peptides




**FIG. 4**

Reduction in HSV1 infectivity after treatment with various concentrations of apolipoprotein derived peptides




**FIG 5**


Reduction in HSV1 infectivity after treatment with various concentrations of apoB derived peptides



**FIG 6**

Reduction in HIV infectivity after treatment of NP2 glioma cells with various concentrations of apoB derived GIN 33, or apoE- derived apoE141-149.



**FIG 7**

**FIG 8**